NEW YORK (GenomeWeb News) – Warnex today announced it has completed the sale of its Analytical Services division to Neopharm Labs.

The deal had an effective date of April 2 and provides Warnex with C$300,000 (US$303,616) in cash proceeds. Under the transaction's terms, Neopharm assumes certain specific undisclosed liabilities related to the division. Subject to certain conditions, Warnex will have the right to terminate the lease for its Laval, Quebec facilities, which are owned by an affiliate of Neopharm, prior to the current expiry date of the lease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."